Skip to content
2000
Volume 13, Issue 4
  • ISSN: 1574-8871
  • E-ISSN: 1876-1038

Abstract

Background: Intravenous treatment with ceftriaxone, a commonly used third-generation cephalosporin, is associated with a risk of the potentially fatal side-effect of neutropenia. Objective: The first systematic study to determine whether six to 12 days' intravenous ceftriaxone treatment is associated with a reduction in the neutrophil count and the extent to which biochemical and/or haematological parameters routinely measured at baseline predict such a fall. Method: Baseline and follow-up haematological and biochemical blood indices were measured in 86 patients (mean age 39.4 years; 55 female) receiving 2 g intravenous ceftriaxone daily. Results: At follow-up, the mean (standard error) neutrophil count had fallen from 3.93 109 (0.16 109) L-1 to 3.15 109 (0.15 109) L-1 (p < 0.000001). This reduction was predictable according to the following multifactor linear regression model: (baseline neutrophil count (109 L-1)) – (follow-up neutrophil count (× 109 L-1)) = 76 + 159.2(baseline haematocrit) – 14.5(baseline red blood cell count (1012 L-1)) – 0.724(baseline mean corpuscular volume (fL)) + 0.474(baseline neutrophil count (109 L-1)) + 0.0448(baseline total iron binding capacity (μM)) + 7.15(baseline calcium ion concentration (mM)) – 13.2(baseline corrected calcium ion concentration (mM)) + 0.0166(baseline alkaline phosphatase (IU L-1)). The residuals were normally distributed and model testing by random partition of the original data into two parts, with training of the model using the first part and model testing with the second part, gave highly satisfactory results. Conclusion: Intravenous ceftriaxone treatment is associated with a fall in neutrophils, which can be predicted by routine baseline blood indices.

Loading

Article metrics loading...

/content/journals/rrct/10.2174/1574887113666180517072744
2018-10-01
2025-10-20
Loading full text...

Full text loading...

/content/journals/rrct/10.2174/1574887113666180517072744
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test